WallStSmart

Johnson & Johnson (JNJ)vsTactile Systems Technology Inc (TCMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Johnson & Johnson generates 27855% more annual revenue ($97.93B vs $350.31M). JNJ leads profitability with a 21.5% profit margin vs 7.1%. JNJ appears more attractively valued with a PEG of 2.79. JNJ earns a higher WallStSmart Score of 59/100 (C).

JNJ

Buy

59

out of 100

Grade: C

Growth: 4.7Profit: 8.5Value: 2.7Quality: 6.0
Piotroski: 4/9Altman Z: 2.64

TCMD

Buy

56

out of 100

Grade: C

Growth: 8.0Profit: 5.5Value: 4.3Quality: 9.0
Piotroski: 5/9Altman Z: 4.80
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

JNJSignificantly Overvalued (-88.9%)

Margin of Safety

-88.9%

Fair Value

$140.57

Current Price

$265.58

$125.01 premium

UndervaluedFair: $140.57Overvalued

Intrinsic value data unavailable for TCMD.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

JNJ5 strengths · Avg: 8.8/10
Market CapQuality
$640.02B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
24.8%9/10

Every $100 of equity generates 25 in profit

Profit MarginProfitability
21.5%9/10

Keeps 22 of every $100 in revenue as profit

Operating MarginProfitability
29.2%8/10

Strong operational efficiency at 29.2%

Free Cash FlowQuality
$3.39B8/10

Generating 3.4B in free cash flow

TCMD4 strengths · Avg: 9.5/10
EPS GrowthGrowth
144.1%10/10

Earnings expanding 144.1% YoY

Debt/EquityHealth
0.0610/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
4.8010/10

Safe zone — low bankruptcy risk

Price/BookValuation
2.3x8/10

Reasonable price relative to book value

Areas to Watch

JNJ3 concerns · Avg: 2.7/10
P/E RatioValuation
30.9x4/10

Premium valuation, high expectations priced in

PEG RatioValuation
2.792/10

Expensive relative to growth rate

EPS GrowthGrowth
-0.9%2/10

Earnings declined 0.9%

TCMD3 concerns · Avg: 2.7/10
Market CapQuality
$495.41M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
7.1%3/10

7.1% margin — thin

PEG RatioValuation
17.792/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : JNJ

The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.5% and operating margin at 29.2%.

Bull Case : TCMD

The strongest argument for TCMD centers on EPS Growth, Debt/Equity, Altman Z-Score.

Bear Case : JNJ

The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.

Bear Case : TCMD

The primary concerns for TCMD are Market Cap, Profit Margin, PEG Ratio.

Key Dynamics to Monitor

JNJ profiles as a mature stock while TCMD is a value play — different risk/reward profiles.

TCMD carries more volatility with a beta of 0.79 — expect wider price swings.

TCMD is growing revenue faster at 8.6% — sustainability is the question.

JNJ generates stronger free cash flow (3.4B), providing more financial flexibility.

Bottom Line

JNJ scores higher overall (59/100 vs 56/100), backed by strong 21.5% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Johnson & Johnson

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.

Visit Website →

Tactile Systems Technology Inc

HEALTHCARE · MEDICAL DEVICES · USA

Tactile Systems Technology, Inc., a medical technology company, is dedicated to the development and supply of medical devices for chronic diseases in the United States. The company is headquartered in Minneapolis, Minnesota.

Want to dig deeper into these stocks?